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total knee replacement surgery and from 2 cadaveric donors with- 
out macroscopic signs of arthritis. All procedures were approved 
by the hospital's ethical committee. Bovine articular chondrocytes 
were isolated from calf paws. After isolation, either human or 
bovine chondrocytes were plated in 6-well plates at high den- 
sity to prevent dedifferentiation. Inducible nitric oxide synthase 
(iNOS) and IKB-o~ protein levels were evaluated in the cytoplas- 
mic extracts by Western blot. 
Results: iNOS was detected in 61.5% (8 out of 13) of the OA 
samples, whereas it was undetectable in all of the normal sam- 
ples (n=2). Furthermore, iNOS was detected in OA cells treated 
with Interleukin-ll~ (IL-1), 10 ng/ml for 5 min, but not in those 
treated for 15 min or longer. Five out of the 80A samples that 
showed detectable iNOS levels also had detectable levels of IKB- 
o~. The amount of IKB-o~ in those samples was identical to that 
found in the normal samples. To evaluate the role of NO pro- 
duced by iNOS on NF-KB activation, bovine articular chondro- 
cytes were pretreated with IL-1, 5 ng/ml for 16 h to induce iNOS 
expression and thus mimic the conditions observed in OA chon- 
drocytes. Then, the cells were treated with a second IL-1 stimu- 
lus for 30 min in the presence or absence of the NOS inhibitor, 
N-monomethyI-L-arginine (NMMA, 250 mM). The cytoplasmic ex- 
tracts were used to detect the levels of IKB-o~, as an indicator of 
NF-KB activation. The amount of IKB-o~ detected in the cytoplas- 
mic extracts from chondrocytes treated with the second IL-1 stim- 
ulus in the presence of NMMA was lower than that found in cells 
treated with IL-1 alone, indicating that the absence of NO facili- 
tates IL-1-induced NF-KB activation. 
Conclusions: Our previous studies showed that NO inhibits IL- 
l -induced NF-KB activation and iNOS expression in bovine chon- 
drocytes. The results presented here indicate that in human chon- 
drocytes NO may also regulate NF-KB activation, as indicated by: 
1) the concomitant presence of iNOS and IKB-o~ in the majority of 
the OA samples, implying that NO produced by iNOS may con- 
tribute to prevent IKB-o~ degradation, 2) the rapid degradation of 
iNOS that occurs in response to IL-1 and, thus, terminates NO 
production, and 3) the increased IKB-o~ degradation that occurs 
when iNOS activity is inhibited by NMMA. Since inflammatory 
stimuli, like IL-1, overcome the inhibitory effect of NO by induc- 
ing iNOS degradation, addition of NO may help preventing their 
effects in chondrocytes. This may be an explanation for the in- 
creased anti-inflammatory activity of the new "NO-aspirin" com- 
pounds relatively to their parent drugs. 
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Introduction: In advanced osteoarthritis, presence of pannus like 
tissue is characterized by hyperplasia of synovial fibroblasts. Re- 
cently, it has been shown that intimal ining cells of synovium and 
fibroblast-like synoviocytes express the B cell activating proteins, 
BAFF and APRIL, and that their expression is augmented by cy- 
tokines. This study was undertaken to examine the expression of 
APRIL/BAFF in OA and RA synovium, and to examine the biolog- 
ical effects of these "B cell activators" on fibroblast functions. 
Methods: Synovial tissue was obtained from OA patients un- 
dergoing joint replacement surgery. Fibroblast-like synovial cells 
were isolated from synovium using collagenase digestion and cul- 
tured in synoviocyte growth medium. Synovial fibroblast passage 
5-7 was used for all the studies. Prostaglandin E2 (PGE2), IL- 
6 and IL-8 production were estimated using radioimmunoassay 
and ELISA respectively. Gene expression studies of synovial tis- 
sues from normal, OA and RA patients were performed using 
Affymetrix U133A and B microarray. 
Results: Expression of APRIL and BAFF was analyzed in nor- 
mal, OA and RA synovial tissues using microarray. Transcripts 
for both APRIL and BAFF were expressed in all synovial tissues; 
however, only BAFF was differentially upregulated in RA (3 fold) 
and OA (1.5 fold) synovium compared to normal. The addition of 
APRIL (200ng/ml) and BAFF (50ng/ml) to synovial fibroblasts in- 
duced significant production of PGE2: 1.6ng/ml baseline to 5 and 
8.5ng/ml, respectively (p<0.01). Similarly, both APRIL and BAFF 
induced IL-6 and IL-8 production by cultured synovial fibroblast. 
These stimulatory effects were dose dependent over the range of 
50 - 1000ng/ml for each inflammatory mediator examined. The 
fold-increase of PGE2 following exposure to APRIL and BAFF 
was comparable to that induced by TNFa (100ng/ml). The induc- 
tion of PGE2, IL-6 and IL-8 byAPRIL were each attenuated (>50- 
85% inhibition, p<0.01 ) by a neutralizing antibody specific for the 
APRIL/BAFF receptor, BCMA. 
Conclusion: The B-cell activating factors, APRIL and BAFF are 
expressed by cells of OA and RA synovial tissue, where they 
trans activate synovial fibroblasts, inducing the production of in- 
flammatory mediators. Neutralizing agents against APRIL and 
BAFF may have therapeutic value in arthritis by blocking synovial 
tissue activation that promotes disease progression. 
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Aim of Study: Fibroblast growth factor-2 (FGF-2) is a candidate 
to regenerate articular cartilage tissue due to its anabolic effects 
on chondrocytes. On the contrary, FGF-2 is involved in pathogen- 
esis of rheumatoid arthritis, in which joint is destructed. The aim 
is to clarify whether effects of FGF-2 on joints are anabolic or 
catabolic. 
Methods 1) Radiolabeled human recombinant FGF-2 was in- 
jected into a knee joint of C57BI/10 mice (10 weeks old) to ex- 
amine when and where the injected FGF-2 was attached. 2) A 
high or low dose of FGF-2 (5 I~g or 4 ng), or control solution was 
injected intra-articularly. The joints were harvested various timing 
after the injection to examine the time course of the histological 
changes. 3) Various doses of FGF-2 were injected in order to ex- 
amine the dose-dependency of the effects. 
Results: Radiolabeled FGF-2 was detected in the superficial and 
intermediate zones of the articular cartilage (Fig. 1A) as well as 
in the synovium and perichondrium (Fig. 1B, 1C). The binidng 
peaked 4 hours after the injection and was transient. An FGF-2 
(51~g) injection caused synovial hyperplasia djacent o the artic- 
ular cartilage on day 7. Cartilage based on the periarticular bone 
was observed on day 14 (Fig. 2B, Fig.2A before the injection), 
and osteophyte with articular surface on day 21 (Fig. 2C). Inten- 
sity of safranin-O staining of the articular cartilage increased sig- 
nificantly on day 14 and 21. The relative intensity peaked on day 
14, and was significantly higher in the joint injected with a high 
dose of FGF-2 than in the control joint on days 14 and 21. Various 
doses of FGF-2 were injected once into the knee joints and the 
knee joints were harvested two weeks after the injection. Histo- 
